Researchers have discovered a drug combination that may offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer. An oncogene called MYC is amplified in these tumors making them very susceptible to recurrence. In addition, there’s a greater risk of it spreading to other areas of the brain and down the spine,The five-year survival rate of this cancer is less than 45 percent. We wanted to discover better treatment options for these kids.
Mitra’s team discovered that two drugs which have already cleared phase I safety trials in other solid tumors have a significant impact on these tumors when used together.
Using the epigenetic drug tacedinaline, the team discovered that in addition to making tumors grow MYC was also hiding the tumors from the various immune cells in the body. They were able to unblock what are referred to as ‘don’t eat me pathways’ that prevent macrophages in the immune system from consuming a tumor.
Then they made the tumor more enticing. When they used tacedinaline to unblock those pathways, and then added anti-CD47, a drug which makes macrophages become super eaters, the tumor became extremely appetizing to the macrophages enticing them to eat the tumor that was unblocked. You are essentially harnessing the body’s own immune system by giving it a jumpstart, much like a medical version of PacMan.
